No association between CYP3A4*22 and statin effectiveness in reducing the risk for myocardial infarction.
Leusink M, de Keyser CE, Onland-Moret NC, Hofman A, Visser LE, Stricker BH, de Bakker PI, de Boer A, van Schaik RH, Maitland-van der Zee AH.
Leusink M, et al. Among authors: de keyser ce, de bakker pi, de boer a.
Pharmacogenomics. 2014 Aug;15(11):1471-7. doi: 10.2217/pgs.14.90.
Pharmacogenomics. 2014.
PMID: 25303298